论文部分内容阅读
目的观察氨溴特罗口服液治疗儿童咳嗽变异性哮喘的疗效。方法将150例咳嗽变异性哮喘患儿随机分为对照组和观察组,每组75例,对照组口服孟鲁司特钠及舒喘灵片,观察组口服孟鲁司特钠及氨溴特罗口服液,比较两组疗效。结果观察组咳嗽消失时间明显短于对照组(P<0.05);观察组总有效率(89.3%)高于对照组(76%),两组比较差异有统计学意义(χ2=4.6526,P<0.05);对照组不良反应发生率高于对照组(χ2=4.7535,P<0.05)。结论氨溴特罗口服液在儿童咳嗽变异性哮喘治疗中疗效显著,且不良反应少,值得临床推广。
Objective To observe the efficacy of ambroxol oral solution in treating children with cough variant asthma. Methods 150 cases of cough variant asthma children were randomly divided into control group and observation group, 75 cases in each group, the control group oral montelukast sodium and Shuchuanling tablets, the observation group oral montelukast sodium and ammonia bromine Luo oral solution, the two groups were compared. Results The disappearance time of cough in the observation group was significantly shorter than that in the control group (P <0.05). The total effective rate (89.3%) in the observation group was higher than that in the control group (76%), the difference was statistically significant (χ2 = 4.6526, P < 0.05). The incidence of adverse reactions in the control group was higher than that in the control group (χ2 = 4.7535, P <0.05). Conclusion Ambroxol oral solution has significant curative effect in the treatment of children with cough variant asthma with less adverse reactions and is worthy of clinical promotion.